NCT02642926

Brief Summary

Since the development a few years ago of bipolar energy in the surgery by operative hysteroscopy, the hysteroscopic treatment of menorrhagia by endometrial ablation can be achieved either by the use of monopolar or bipolar current, in parallel with other techniques labelled as 'second generation' (microwave, radio frequency, thermal destruction ...) treating the uterine cavity. It seems that the use of the bipolar energy decreases the rate of adhesions but prospective data on the success rate after bipolar endometrial ablation are poor and there is currently no recommendation as to the choice of technique to use. No prospective assessment exists to date in the literature to compare the difference in efficacy on bleedings when using monopolar or bipolar current. The goal of this study is to compare these two energies, by measuring the amount of bleeding calculated by the Higham score 12 months after the intervention.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
98

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Dec 2012

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2012

Completed
3 years until next milestone

First Submitted

Initial submission to the registry

December 11, 2015

Completed
19 days until next milestone

First Posted

Study publicly available on registry

December 30, 2015

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2016

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2016

Completed
Last Updated

August 8, 2016

Status Verified

August 1, 2016

Enrollment Period

3.7 years

First QC Date

December 11, 2015

Last Update Submit

August 5, 2016

Conditions

Keywords

menorrhagiahigham PBAC scoreendometrial ablationbipolar energymonopolar energy

Outcome Measures

Primary Outcomes (1)

  • Bleeding abundance

    Bleeding abundance will be measured by the Higham score, on a questionnaire sent to the patient.

    12 months after surgical intervention

Secondary Outcomes (5)

  • Bleeding abundance

    6 months after surgical intervention

  • Surgery duration

    From the entry till the removal of the hysteroscope from the body -ambulatory surgery (max one day)

  • Per-operative complications rate

    From the entry till the removal of the hysteroscope from the body - ambulatory surgery (max one day)

  • Post-operative complications rate

    6 weeks after the surgical intervention

  • Re-do surgery rate

    12 months after the surgical intervention

Study Arms (2)

Monopolar endoscopic endometrial ablation

ACTIVE COMPARATOR
Procedure: Monopolar current

Bipolar endoscopic endometrial ablation

EXPERIMENTAL
Procedure: Bipolar current

Interventions

Hysteroscopic surgical treatment of menorrhagia by use of monopolar current

Monopolar endoscopic endometrial ablation

Hysteroscopic surgical treatment of menorrhagia by use of bipolar current

Bipolar endoscopic endometrial ablation

Eligibility Criteria

Age18 Years+
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients suffering from menorrhagia
  • Higham score \> 150
  • No further pregnancy wish
  • Failure of a former medical treatment
  • Patients consulting a surgeon, for a standard of care surgical intervention

You may not qualify if:

  • Pregnant women
  • Menopausal women
  • Patient under anticoagulant treatment, type anti-vitamin K (AVK)
  • Patient with a malign endometrial pathology
  • Patient with one or several known endo-uterine synechia
  • Uterine malformation
  • Active and uncured infection

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

CHU Bicêtre, Kremlin Bicêtre (A.P.H.P)

Bicêtre, 94270, France

Location

Related Publications (7)

  • Duckitt K. Menorrhagia. BMJ Clin Evid. 2015 Sep 18;2015:0805.

    PMID: 26382038BACKGROUND
  • Higham JM, O'Brien PM, Shaw RW. Assessment of menstrual blood loss using a pictorial chart. Br J Obstet Gynaecol. 1990 Aug;97(8):734-9. doi: 10.1111/j.1471-0528.1990.tb16249.x.

    PMID: 2400752BACKGROUND
  • Fergusson RJ, Lethaby A, Shepperd S, Farquhar C. Endometrial resection and ablation versus hysterectomy for heavy menstrual bleeding. Cochrane Database Syst Rev. 2013 Nov 29;(11):CD000329. doi: 10.1002/14651858.CD000329.pub2.

    PMID: 24288154BACKGROUND
  • Boe Engelsen I, Woie K, Hordnes K. Transcervical endometrial resection: long-term results of 390 procedures. Acta Obstet Gynecol Scand. 2006;85(1):82-7. doi: 10.1080/00016340500424314.

    PMID: 16521686BACKGROUND
  • Brumsted JR, Blackman JA, Badger GJ, Riddick DH. Hysteroscopy versus hysterectomy for the treatment of abnormal uterine bleeding: a comparison of cost. Fertil Steril. 1996 Feb;65(2):310-6. doi: 10.1016/s0015-0282(16)58091-1.

    PMID: 8566254BACKGROUND
  • Mayor S. NICE says hysterectomy must be last option for heavy menstrual bleeding. BMJ. 2007 Jan 27;334(7586):175. doi: 10.1136/bmj.39105.376412.DB. No abstract available.

    PMID: 17255588BACKGROUND
  • Berg A, Sandvik L, Langebrekke A, Istre O. A randomized trial comparing monopolar electrodes using glycine 1.5% with two different types of bipolar electrodes (TCRis, Versapoint) using saline, in hysteroscopic surgery. Fertil Steril. 2009 Apr;91(4):1273-8. doi: 10.1016/j.fertnstert.2008.01.083. Epub 2008 Apr 18.

    PMID: 18371962BACKGROUND

MeSH Terms

Conditions

Menorrhagia

Condition Hierarchy (Ancestors)

Uterine HemorrhageUterine DiseasesGenital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital DiseasesHemorrhagePathologic ProcessesPathological Conditions, Signs and SymptomsMenstruation Disturbances

Study Officials

  • André Nazac, MD

    CHU Brugmann

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Head of clinic

Study Record Dates

First Submitted

December 11, 2015

First Posted

December 30, 2015

Study Start

December 1, 2012

Primary Completion

August 1, 2016

Study Completion

August 1, 2016

Last Updated

August 8, 2016

Record last verified: 2016-08

Locations